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Key Points Summary 62 
 Voltage-gated sodium channels play a fundamental role in determining neuronal 63 
excitability 64 
 Specifically, voltage-gated sodium channel subtype NaV1.7 is required for sensing 65 
acute and inflammatory somatic pain in mice and humans but its significance in 66 
pain originating from the viscera is unknown. 67 
 Using comparative behavioural models evoking somatic and visceral pain 68 
pathways, we identify the requirement for NaV1.7 in regulating somatic (noxious 69 
heat pain threshold) but not in visceral pain signalling.  70 
 These results enable us to better understand the mechanisms underlying the 71 
transduction of noxious stimuli from the viscera, suggest that the investigation of 72 
pain pathways should be undertaken in a modality-specific manner and help to 73 
direct drug discovery efforts towards novel visceral analgesics. 74 
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Abstract 75 
Voltage-gated sodium channel NaV1.7 is required for acute and inflammatory pain in 76 
mice and humans but its significance for visceral pain is unknown. Here we examine the 77 
role of NaV1.7 in visceral pain processing and the development of referred hyperalgesia 78 
using a conditional nociceptor-specific NaV1.7 knockout mouse (NaV1.7Nav1.8) and 79 
selective small-molecule NaV1.7 antagonist PF-5198007. NaV1.7Nav1.8 mice showed 80 
normal nociceptive behaviors to intracolonic application of either capsaicin or mustard 81 
oil, stimuli known to evoke sustained nociceptor activity and sensitization following 82 
tissue damage, respectively. Normal responses following induction of cystitis by 83 
cyclophosphamide were also observed in both NaV1.7Nav1.8 and littermate controls. Loss, 84 
or blockade, of NaV1.7 did not affect afferent responses to noxious mechanical and 85 
chemical stimuli in nerve-gut preparations in mouse, or following antagonism of NaV1.7 86 
in resected human appendix stimulated by noxious distending pressures. However, 87 
expression analysis of voltage-gated sodium channel α subunits revealed NaV1.7 mRNA 88 
transcripts in nearly all retrogradely-labelled colonic neurons suggesting redundancy in 89 
function. By contrast, using comparative somatic behavioral models we identify that 90 
genetic deletion of NaV1.7 (in NaV1.8-expressing neurons) regulates noxious heat pain 91 
threshold and that this can be recapitulated by the selective NaV1.7 antagonist PF-92 
5198007. Our data demonstrates that NaV1.7 (in NaV1.8-expressing neurons) 93 
contributes to defined pain pathways in a modality-dependent manner, modulating 94 
somatic noxious heat pain but is not required for visceral pain processing, and 95 
advocates that pharmacological block of NaV1.7 alone in the viscera may be insufficient 96 
in targeting chronic visceral pain. 97 
 98 
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Abbreviations 99 
BSA Bovine serum albumin 
CIP Congenital insensitivity to pain 
CT Quantification cycles 
DRG Dorsal root ganglia 
FB Fast Blue 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase  
IC/BPS Interstitial cystitis/bladder pain syndrome 
LS Lumbosacral 
NaV Voltage-gated sodium channel 
PEPD Paroxysmal extreme pain disorder 
PO Per os 
QST Quantitative standardized testing 
TL Thoracolumbar 
TRPV1 Transient receptor potential cation channel V1 
TTX-R Tetrodotoxin-resistant 
TTX-S Tetrodotoxin-sensitive 
 100 
6 
 
Introduction  101 
Chronic pain originating from internal organs affects significant proportions of the 102 
population with analgesics restricted by dose-limiting side-effects. Persistent pain and 103 
visceral hypersensitivity manifests as reduced thresholds for mechanical distension of 104 
visceral organs and are strongly associated with inflammation. The targeting of 105 
peripheral sensory input, either by peripheral nerve block (Cherry et al., 1985; Brown, 106 
1989; Eisenberg et al., 1995) or local anaesthetics (Verne et al., 2003; Verne et al., 2005) 107 
has proven effective in treating visceral pain. However, our understanding of key 108 
sensory afferent transduction mechanisms responsible for visceral nociception is 109 
limited. Here, we investigate voltage-gated sodium channel NaV1.7 in both visceral and 110 
somatic pain behaviors and show that peripheral pain pathways of the viscera are 111 
functionally distinct from classical nociceptors, providing evidence supporting 112 
functional diversity of nociception and confirmation that novel analgesic development 113 
must be applied in a mechanism-specific manner. 114 
Rare human genetic conditions link NaV1.7 to pain perception, with loss-of-function 115 
mutations causing congenital insensitivity to pain (CIP) (Cox et al., 2006; Goldberg et al., 116 
2007). Recapitulation of the human painless phenotype using knockout mice genetically 117 
engineered to globally lack NaV1.7 results in complete loss of responses to acute, 118 
inflammatory and neuropathic pain (Gingras et al., 2014). Using tissue-specific NaV1.7 119 
knockout mice (including nociceptor-specific NaV1.7Nav1.8 mice (Nassar et al., 2004), 120 
pan-sensory neuron NaV1.7Advill mice (Minett et al., 2012) and pan-sensory and 121 
sympathetic neuron NaV1.7Wnt1 mice (Minett et al., 2012)) modality-specific pain 122 
pathways associated with acute heat and mechanical detection, hyperalgesia and 123 
allodynia have been linked with differing NaV repertoires.  124 
7 
 
Intriguingly, CIP patients feel no visceral pain with reports of both painless childbirth 125 
and rupture of appendix (Melzack & Wall, 1988; Zimmermann et al., 1988; Wheeler, 126 
2015), suggesting that NaV1.7 may be required for visceral nociception. Rectal pain is a 127 
symptom of paroxysmal extreme pain disorder (PEPD), another condition associated 128 
with rare NaV1.7 mutations (Fertleman et al., 2006), with defecation capable of 129 
triggering pain attacks implicating a link to anorectal distension. In patients with 130 
interstitial cystitis/bladder pain syndrome (IC/BPS), pain perception associates with 131 
NaV1.7 mutations (Reeder et al., 2013). Like other chronic pain conditions, a hallmark of 132 
IC/BPS is ongoing pain in the absence of obvious pathophysiology (Dimitrakov & 133 
Guthrie, 2009). Therefore NaV1.7 could be involved in maintaining spontaneous pain, 134 
such as peripheral or central sensitization, in addition to evoked pain attributed to 135 
mechanical stimulation. Surprisingly, whilst broad-spectrum sodium channel blockers 136 
are effective in treating chronic visceral pain, selective NaV1.7 antagonists (ProTx-II) 137 
and monoclonal blocking antibodies targeting NaV1.7 have been unable to fully 138 
recapitulate loss of NaV1.7 mutant phenotypes to other chronic pain models 139 
(Schmalhofer et al., 2008; Lee et al., 2014). Indeed, selective antagonism of NaV1.7 with 140 
ProTx-II also failed to block afferent responses to stretch of the colorectum (Feng et al., 141 
2015), suggesting the contribution of NaV1.7 to visceral pain processing is still unclear.  142 
In light of recent findings that NaV1.7 is essential for some (acute heat and mechanical 143 
pain, inflammatory hyperalgesia and neuropathic allodynia), but not all (acute cold pain, 144 
cancer-induced bone pain and oxaliplatin-evoked allodynia) pain modalities, we 145 
investigated visceral pain and referred hyperalgesia using a conditional nociceptor-146 
specific NaV1.7 knockout mouse (NaV1.7Nav1.8) and selective NaV1.7 antagonist PF-147 
5198007. Thus, using comparative behavioral models evoking somatic and visceral pain 148 
pathways we identify specific mechanisms regulating noxious heat pain threshold and 149 
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show that NaV1.7 in NaV1.8-expressing neurons is not required for visceral pain 150 
signalling.  151 
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Materials and Methods 152 
Experiments were performed in adult mice weighing 20 – 35 g. Conditional nociceptor-153 
specific NaV1.7 knockout mice (NaV1.7Nav1.8) and their littermate controls were 154 
generated as described previously (Nassar et al., 2004). Observers performing 155 
behavioral and ex vivo electrophysiological experiments were blind to the genotypes of 156 
the animals. Animals were acclimatized for at least one week before behavioral testing 157 
in temperature and light-controlled (12hr light/dark cycle) rooms. All experiments 158 
were performed in accordance with the UK Animals (Scientific Procedures) Act of 1986 or 159 
with the EU Directive 2010/63/EU for animal experimentation, with approval of the 160 
University of Granada Research Ethics Committee (Granada, Spain). Human tissues were 161 
collected and utilised with approval of the East London and The City HA Local Research 162 
Ethics Committee (London, UK; NREC 10/H0703/71) in accordance with the Declaration 163 
of Helsinki and following full written informed consent.  164 
Behavioral experiments  165 
Experiments were performed on both male and female knockout and wild-type 166 
littermate control mice. Visceral pain and referred hyperalgesia was assessed using 167 
previously described methods, with small modifications (Olivar & Laird, 1999; Laird et 168 
al., 2001; Gonzalez-Cano et al., 2013). Briefly, mice were acclimatized for 40 minutes to 169 
test chambers (consisting of a transparent box on an elevated wire mesh floor) after 170 
which 50μl of capsaicin (0.1 or 1%), mustard oil (0.01 or 0.1%) or vehicle was instilled 171 
intrarectally via a thin cannula inserted into the anus and the animal returned to the 172 
chamber. The number of spontaneous pain behaviors (including licking of abdomen, 173 
stretching of abdomen and abdominal retractions) were recorded for the subsequent 20 174 
minutes. In a separate set of experiments, visceral pain behaviors caused by 175 
cyclophosphamide-induced cystitis were examined following a previously described 176 
10 
 
protocol (Olivar & Laird, 1999). Again after a 40 min habituation, animals were 177 
removed from the test chamber and cyclophosphamide (100 or 200mg/kg) or vehicle 178 
injected intraperitoneally. The animals were returned to the chamber and pain 179 
behaviors recorded according to the following scale: 0 = normal, 1 = piloerection, 2 = 180 
strong piloerection, 3 = labored breathing, 4 = licking of the abdomen and 5 = stretching 181 
and contraction of the abdomen. If more than one of these behaviors was noted during a 182 
single observation period, then only the type and not quantity of each different pain 183 
behavior was scored (i.e. if two stretching and contractions (5 points) and one 184 
abdominal licking (4 points) was observed, then a score of 9 was assigned).  185 
After the evaluation of spontaneous pain behaviors (primary behavioral endpoint), the 186 
presence of referred hyperalgesia was determined by measuring the withdrawal 187 
response to a punctate mechanical stimulation (von Frey hair filaments 0.02 – 2 g (0.19-188 
19.6 mN), Touch-Test Sensory Evaluators, North Coast Medical Inc., USA) of the 189 
abdomen using the up-down paradigm 20 minutes after algogen administration 190 
(Chaplan et al., 1994). Avoiding the perianal and external genitalia, the mid-range 0.4 g 191 
von Frey hair filament was applied (three times for 2-3 sec at 5 sec intervals) to the 192 
lower and mid abdomen. If a positive response (consisting of immediate 193 
licking/scratching of the application site, sharp retraction of the abdomen or jumping) 194 
was observed, then probing was repeated in consecutive tests with a weaker von Frey 195 
filament. By contrast if there was no response to probing then a stronger von Frey 196 
filament was used. Once the withdrawal threshold (secondary behavioral endpoint) was 197 
ascertained, mice were humanely killed by concussion of the brain and cervical 198 
dislocation of the neck.  199 
Electrophysiological recordings of visceral afferent activity 200 
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Nerves innervating murine and human gastrointestinal tissues were isolated and 201 
electrophysiological activity recorded using previously described methods (Peiris et al., 202 
2011; Hockley et al., 2014). Mice were humanely killed by concussion of the brain and 203 
cervical dislocation of the neck. The distal colon with associated lumbar splanchnic 204 
nerves was removed and transferred to a recording chamber superfused (7 ml/min; 32-205 
34 oC) with carbogenated Krebs buffer (in mM: 124 NaCl, 4.8 KCl, 1.3 NaH2PO4, 2.5 206 
CaCl2, 1.2 MgSO4.7H2O, 11.1 glucose, and 25 NaHCO3) supplemented with nifedipine (10 207 
µM), atropine (10μM) and indomethacin (3 µM). The same supplemented Krebs buffer 208 
was used to luminally perfuse (100 µl/min) the colon after cannulation.  209 
To translate murine experimental recordings into human tissue, we recorded extrinsic 210 
nerve activity from resected human appendices. We have previously shown that the 211 
appendix represents a valid human ex vivo model of visceral afferent activity amenable 212 
to the testing of mechanical and chemical stimuli (Peiris et al., 2011). Specifically, the 213 
extrinsic nerves of the appendix are a branch of those innervating the right colon along 214 
the ileocolic artery and represent a readily available tissue in normal non-inflamed (e.g. 215 
from colon cancer resections) states. Resected appendices were obtained from 5 216 
patients undergoing elective surgery at Barts Health NHS Trust, London after full 217 
written consent was attained. Appendices were removed from patients undergoing 218 
right hemicolectomies as part of their normal surgical treatment for bowel cancer or 219 
slow transit constipation (see Table 1 for details) with the permission of the 220 
histopathologist and were returned to the morbid anatomy department after 221 
completion of the studies. Once removed, appendix specimens were immediately placed 222 
in cold Krebs buffer and handled in a comparable manner to mouse distal colon tissues. 223 
Removal of the tip and cannulation enabled intraluminal perfusion, in addition to 224 
superfusion with Krebs buffer (7 mL/min; 32-34 oC) supplemented with 10 µM 225 
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nifedipine and 10 µM atropine. Under a dissection microscope, mesenteric 226 
neurovascular bundles were blunt dissected and associated nerves identified and 227 
cleared of connective tissue. Using borosilicate glass suction electrodes, multi-unit 228 
activity from whole lumbar splanchnic nerves (rostral to the inferior mesenteric 229 
ganglia) of mouse, or from mesenteric nerves of human bowel tissues, was recorded. 230 
Signals were amplified and band pass filtered (gain 5 K; 100-1300 Hz; Neurolog, 231 
Digitimer Ltd, UK) and digitized at 20 kHz (micro1401; Cambridge Electronic Design, 232 
UK) before display on a PC using Spike 2 software. The signal was digitally filtered for 233 
50 Hz noise (Humbug, Quest Scientific, Canada) and a threshold of twice the background 234 
noise (typically 100 µV) was used to determine action potential firing counts.  235 
Electrophysiological protocols 236 
Following a stabilizing period of 30 minutes, noxious intraluminal distending pressures 237 
were applied by blocking the luminal perfusion out-flow of the cannulated mouse distal 238 
colon or resected human appendix. The noxious pressures reached evoke pain 239 
behaviors in vivo and are above threshold for all known visceral afferent 240 
mechanoreceptors (Ness & Gebhart, 1988; Hughes et al., 2009). In murine experiments, 241 
a combined sequential protocol was used to initially assess multiple aspects of visceral 242 
afferent mechanosensitivity and chemosensitivity. Specifically, a set of 6 rapid phasic 243 
distensions (0-80 mm Hg, 60 s at 9 min intervals) followed by slow ramp distension (0-244 
145 mmHg, ~5-6 min) were implemented prior to bath superfusion of separate 20 ml 245 
volumes of 1 μM bradykinin and 1mM ATP at 40 min intervals. In separate experiments, 246 
the effect of pharmacological inhibition of NaV1.7 on visceral afferent sensitivity to 247 
mechanical distension or noxious stimulation by capsaicin, mustard oil or bradykinin 248 
was tested. A set of 9 rapid phasic distensions (0-80 mm Hg, 60 s at 9 min intervals) 249 
followed by a 30 min stabilization period and bath superfusion of 1 μM bradykinin in a 250 
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20 ml volume were performed. Prior to the 7th phasic distension, bath superfusion of 251 
the selective NaV1.7 antagonist PF-5198007 (100 nM; 500 mL; (Alexandrou et al., 252 
2016)) or vehicle (0.1 % DMSO) was initiated and maintained for the duration of the 253 
remaining three distensions and bradykinin application. In some experiments, after a 254 
wash-out period, repeat phasic distensions were performed during which 250 ml 255 
tetrodotoxin (TTX; 100 nM) was superfused. In separate experiments, a ramp 256 
distension (0-145mmHg) was performed followed by bath superfusion of capsaicin 257 
(500nM) and mustard oil (250 μM) at 1 hour interval. Five minutes prior to application 258 
of capsaicin, either 100nM PF-5198007 or vehicle (0.1% DMSO) was applied for the 259 
duration of the subsequent stimulations. Human appendix specimens were stimulated 260 
in a comparable manner by repeat ramp distension (0-60 mm Hg, ~30 s at 9 min 261 
intervals). Baseline responses were established for three distensions prior to the 262 
superfusion of PF-5198007 (100 nM or 1 μM) for 50 min during subsequent 263 
distensions.  264 
Retrograde labelling of gut-specific sensory neurons and single-cell qRT-PCR 265 
Distal colon-specific sensory neurons were retrogradely labelled, picked and the 266 
expression of mRNA transcripts of interest determined by qRT-PCR. A mid-line 1.5cm 267 
laparotomy was performed on male mice after induction of anaesthesia with 1.5% 268 
isoflurane. Multiple injections of Fast Blue (FB: 0.2 μl per site, 2% in saline, Polysciences 269 
Gmbh, Germany) were made using a fine pulled-glass needle and microinfusion pump 270 
(0.4 μl/min) into the wall of the distal colon. Prior to suturing of the peritoneal muscle 271 
layer and securing the skin with Michel clips, the abdominal cavity was flushed with 272 
saline to remove any excess FB. Post-operative care (monitoring body weight and soft 273 
diet) and analgesia (buprenorphine 0.05-0.1 mg/kg daily) was provided for the 274 
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duration of the protocol. Three to five days after surgery, mice were humanely killed by 275 
concussion of the brain and cervical dislocation of the neck, and thoracolumbar (TL: 276 
T10-L1) and lumbosacral (LS: L5-S2) dorsal root ganglia (DRGs) were harvested and 277 
cultured separately for gene expression experiments. Dissected ganglia were incubated 278 
at 37°C (in 5% CO2) in Lebovitz L-15 Glutamax (GIBCO, UK) media containing 1mg/ml 279 
collagenase type 1A (Sigma) and 6mg/ml bovine serum albumin (BSA; Sigma, UK) for 280 
15 min, followed by L-15 media containing 1mg/ml trypsin (Sigma, UK) and 6mg/ml 281 
BSA for 30 min. Ganglia were gently triturated and collected by brief centrifugation at 282 
500 g. The supernatant (containing dissociated cells) was collected and the cycle of 283 
gentle trituration and centrifugation repeated. Cells from TL and LS DRG were plated 284 
separately onto poly-D-lysine–coated coverslips (BD Biosciences, UK) and incubated in 285 
Lebovitz L-15 Glutamax media containing 2 % penicillin/streptomycin, 24 mM NaHCO3, 286 
38mM glucose and 10 % fetal bovine serum. Fast Blue positive colonic sensory neurons 287 
were individually harvested from cultures of retrogradely labelled DRG (either TL: T10-288 
L1 or LS: L5-S2) by pulled glass pipette. By breaking the pipette tip (containing the cell) 289 
into a tube containing preamplification mastermix (2.5μl 0.2x primer/probe mix, 5μl 290 
CellDirect 2x reaction buffer (Invitrogen), 0.1 μl SUPERase-in (Ambion, TX, USA), 1.2 μl 291 
TE buffer (Applichem, Germany) and 0.2 μl Superscript III Reverse 292 
Transcriptase/Platinum Taq mix (Invitrogen)) and freezing immediately, mRNA 293 
transcripts were preserved. Only those individual Fast Blue positive neurons free from 294 
debris and other non-neuronal cells (e.g. satellite glia) were collected. An image of each 295 
harvested neuron was also captured using a camera (DCC1545M, ThorLabs Inc, NJ, USA) 296 
attached to the inverted microscope enabling an estimation of cell size to be 297 
ascertained. In the absence of cells, samples of the bath solution were collected for no-298 
template control experiments. Using the following thermal cycling protocol, 299 
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preamplification of cDNA was achieved: 50°C for 30 minutes, 95°C for 2 minutes, then 300 
21 cycles of (95°C for 15 seconds, 60°C for 4 minutes). After dilution (1:5 TE buffer), 301 
Taqman qPCR assays were run for each gene of interest (Taqman Assay ID: NaV1.1, 302 
Mm00450580_m1; NaV1.2, Mm01270359_m1; NaV1.3, Mm00658167_m1; NaV1.4, 303 
Mm00500103_m1; NaV1.5, Mm01342518_m1; NaV1.6, Mm00488110_m1; NaV1.7, 304 
Mm00450762_s1; NaV1.8, Mm00501467_m1; NaV1.9, Mm00449367_m1; GAPDH, 305 
Mm99999915_g1; Applied Biosystems) using the following cycling protocol: 50°C for 2 306 
minutes, 95°C for 10 minutes, then 40 cycles of (95°C for 15 seconds, 60°C for 1 307 
minutes). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) acted as an internal 308 
positive control, with all single-cell RT-PCR products expressing GAPDH and bath 309 
control samples were negative for all Taqman reactions. Relative expression of NaVs 310 
was normalized to GAPDH quantification cycles (CT) using 2-CT formula. Quantitative 311 
assessment of gene expression was determined by quantification cycle values less than 312 
the threshold of 35 being considered as positive.  313 
Ramping hotplate pain behaviors  314 
Behavioral phenotyping experiments were performed using both male and female mice, 315 
and pharmacology experiments were carried out in male mice. Acute heat pain was 316 
assessed using a ramping hotplate comparable to that used in human standardised 317 
quantitative testing (QST) protocols (Rolke et al., 2006). Mice were acclimatized in a 318 
chamber for 6 minutes daily for the 3 days preceding dosing. After which, following a 30 319 
second acclimatization, the chamber floor was slowly heated from 31°C at a rate of 320 
3.4°C/min and the temperature and time taken until observing a pain behavior was 321 
recorded (behavioral endpoint; the occurrence of either licking or shaking of the hind 322 
paw and/or rapid shifting of weight (stomping) from one foot to the other). After 323 
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baseline measurements were made, mice were dosed via oral administration (P.O.) with 324 
either vehicle or PF-5198007 at 1 or 3mg/ml with a dose volume of 10ml/kg and 1hr 325 
later, the ramping hotplate repeated. Mice were humanely killed by concussion of the 326 
brain and cervical dislocation of the neck immediately after final assessment of thermal 327 
pain threshold. 328 
Skin-nerve preparation 329 
Multi-unit extracellular afferent recordings were made from the tibial nerve innervating 330 
the glaborous skin of the hind paw as previously described (Milenkovic et al., 2008) but 331 
with some modifications. Briefly, mice were humanely killed by concussion of the brain 332 
and cervical dislocation of the neck, the hind limbs were then shaved, removed and the 333 
tibial nerve and associated glaborous skin dissected free. The preparation was mounted 334 
glaborous skin downwards in a recording chamber superfused (10ml/min; 36±1˚C) 335 
with carbogenated (95% O2, 5% CO2) Krebs buffer (in mM: NaCl 107, KCl 3.48, NaHCO3 336 
26.2, MgSO4(.7H2O) 0.69, NaH2PO4 1.67, Na-gluconate 9.64, sucrose 7.6, glucose 5.5, 337 
CaCl 1.53). The epiperineurium was removed from the distal end of the tibial nerve and 338 
suction electrode recordings comparable to those of visceral afferent activity were 339 
made. Following a 60 minute stabilisation period, a heat stimulus (Krebs perfused onto 340 
the skin at a focal point equivalent to the heel portion of the paw) lasting 50 seconds 341 
was applied, this increased in temperature from 36˚C to 52˚C at a rate of 0.4˚C/second 342 
to mimic the noxious heat ramp used in vivo. In total, a series of 10 heat stimulations 343 
were performed at 15 minutes intervals. The first 4 heat stimulation formed the 344 
baseline reading with bath superfusion of PF-5198007 (30nM) or vehicle (0.1% DMSO) 345 
initiated and maintained for the duration of the next 2 stimulations (30 minutes), PF-346 
5198007 (100nM) or vehicle (0.1% DMSO) for the following 2 heat stimulations (30 347 
minutes) and heat stimulations 9 and 10 carried out during the superfusion (15 348 
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minutes) of TTX (100nM or 300nM) and lidocaine (1mM), respectively. In separate 349 
experiments, the effect of genotype and selective sodium channel antagonists were 350 
assessed in response to a cold stimulus (36 to 6˚C at a rate of 0.4˚C/second) delivered in 351 
the same manner as the heat stimulus, with comparable stimulation and protocols as 352 
above. 353 
Data analysis 354 
Pain behaviors and mechanical thresholds were compared across experimental groups 355 
with 2-way analysis of variance (ANOVA) followed by the Bonferroni post-hoc test, 356 
using either SigmaPlot 12.0 (Systat Software Inc., CA, USA) or Prism 6 (GraphPad Inc., 357 
USA). Referred hyperalgesia, expressed as the mechanical threshold producing 50% of 358 
responses, was calculated using: 50% mechanical threshold (g)  [(10 (Xf + κδ)) /10], 359 
where Xf  value (in logarithmic units) of the final von Frey filament used; κ  tabular 360 
value for the pattern of positive/negative responses; and δ  mean difference (in log 361 
units) between stimuli (Dixon, 1980). Peak changes or total sum firing of 362 
electrophysiological nerve activity in multi-unit experiments were determined by 363 
subtracting baseline firing (2 minutes before distension or drug application) from 364 
increases in nerve activity following distension or noxious chemical superfusion. 365 
Estimation of cell size from single-cell images was achieved by averaging the height and 366 
width of each cell (ImageJ 1.49V analysis software, NIH, USA). Total sum firing of 367 
electrophysiological nerve activity in response to each hot or cold stimulation was 368 
obtained by subtracting any signal evoked by heat/cold stimulation in the presence of 369 
lidocaine (1mM). Expression data was visualized using R and the ggplot2 graphics 370 
package (Wickham, 2009). Statistical significance was set at P < 0.05. Data are displayed 371 
as mean ± SEM. 372 
Drugs 373 
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Stock concentrations of capsaicin (1%; 10% ethanol, 10% tween, 80% saline), mustard 374 
oil (1%; 70% ethanol, 30% saline), cyclophosphamide (saline), bradykinin (10mM; 375 
water), lidocaine (1M; water) and ATP (300mM; water) were purchased from Sigma-376 
Aldrich and prepared as described. Tetrodotoxin (15μg/ml stock) was purchased from 377 
Nanning Leaf Pharmaceuticals (Canada) and diluted in saline. PF-5198007 was 378 
manufactured in-house by Pfizer and solubilized in DMSO at a 10mM stock. For in vitro 379 
experiments, PF-5198007 was applied at a concentration of 100nM (ensuring almost 380 
100% inhibition of mouse NaV1.7 (IC50 5.2nM) and selectivity over NaV1.1 and NaV1.6 381 
(IC50 149nM and 174nM, respectively)(Alexandrou et al., 2016)). For in vivo studies PF-382 
5198007, 1mg/ml or 3mg/ml, was suspended in 0.5% methylcellulose + 0.1% Tween-383 
80 in distilled water. Doses of PF-5198007 were selected to achieve a free plasma 384 
concentration of ~100nM (littermate: 1mg/kg, 58 ± 10 nM, N = 5; 3mg/kg, 842 ± 91 nM, 385 
N = 10; NaV1.7Nav1.8: 1mg/kg, 68 ± 12 nM, N = 5; 3mg/kg, 634 ± 69 nM, N = 9). Vehicle 386 
was dosed as a 10ml/kg solution of 0.5% methylcellulose + 0.1% Tween-80 in distilled 387 
water. All other compounds were diluted in appropriate experimental buffer to working 388 
concentrations on the day of experimentation, unless otherwise stated.  389 
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Results 390 
Visceral pain behaviors to colorectal sensitizing noxious stimuli were unaffected 391 
by deletion of NaV1.7  392 
We used a conditional NaV1.7 knockout mouse strain, where floxed (SCN9A) NaV1.7 mice 393 
were crossed with mice in which Cre expression is driven by the NaV1.8 promotor 394 
(NaV1.7Nav1.8) resulting in tissue-specific ablation of NaV1.7 in sensory neurons 395 
expressing nociceptive markers (Nassar et al., 2004; Shields et al., 2012). Capsaicin acts 396 
at TRPV1 and will activate the vast majority of visceral afferent terminals (>85% 397 
(Christianson et al., 2006; Malin et al., 2009)) leading to neurogenic inflammation and 398 
prolonged ongoing afferent activity due to sensitization (Laird et al., 2001; Laird et al., 399 
2002). Intracolonic instillation of capsaicin in littermate control mice led to dose-400 
dependent increases in observed pain behaviors consisting of abdominal contractions 401 
and licking (Fig. 1A). The deletion of NaV1.7 from NaV1.8-positive neurons, however, did 402 
not attenuate pain behaviors at either dose of capsaicin tested (P = 0.72, N = 6-8, 2-way 403 
ANOVA). In separate experiments, the potent algogen mustard oil was instilled 404 
intracolonically leading to the activation and sensitization of afferents and induction of 405 
localized tissue damage as previously described (Laird et al., 2002). Substantial pain 406 
behaviors were observed in both NaV1.7Nav1.8 and littermate controls (Fig. 1B), which 407 
were not significantly different in terms of the magnitude of their response (P = 0.79, N 408 
= 6-8, 2-way ANOVA). The time course of pain behaviours induced by capsaicin and 409 
mustard oil did not differ between littermate controls and NaV1.7Nav1.8 mice. These 410 
findings show that NaV1.7 expressed in NaV1.8-positive neurons is not required for the 411 
development of visceral pain or for sustained spontaneous nociceptor activity as a 412 
result of sensitization.  413 
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Referred hyperalgesia is a common characteristic of visceral pain, with the sensitization 414 
of somatic structures in the same metameric field to the affected organ driven in part by 415 
spinal convergence of somatic and visceral afferents inputs (Cervero, 1983; Mertz et al., 416 
1995). Whilst primary inflammatory hyperalgesia has been shown to be dependent on 417 
NaV1.7 in NaV1.8-expressing neurons, whether NaV1.7 contributes to the development of 418 
secondary hyperalgesia remains unstudied. The development of mechanical sensitivity 419 
of the abdomen in response to intracolonic instillation of either capsaicin (0.1%) or 420 
mustard oil (0.01%) was independent of ablation of NaV1.7 from NaV1.8-expressing 421 
neurons, with 50% withdrawal thresholds significantly reduced 20 minutes after 422 
treatment irrespective of genotype (capsaicin; P < 0.01, N = 6-8, 2-way ANOVA; mustard 423 
oil, P < 0.01, N = 6-8, 2-way ANOVA).  424 
Pain responses to cyclophosphamide-induced cystitis are unaffected by deletion 425 
of NaV1.7 426 
To model bladder pain/cystitis in NaV1.7Nav1.8 mice, cyclophosphamide was 427 
administered leading to the progressive development of visceral pain behaviors for the 428 
duration of the 4 hour observation window. Cyclophosphamide treatment produces 429 
mucosal erosion and haemorrhage of the bladder in addition to edema (Fraiser et al., 430 
1991). The development and time course of pain behaviors observed did not differ 431 
between littermate controls and NaV1.7Nav1.8 mice to either dose of cyclophosphamide 432 
tested (Fig. 2A, P = 0.93, N = 6-8, 2-way ANOVA). Indeed both NaV1.7Nav1.8 mice and 433 
littermate controls also showed marked referred hyperalgesia when tested 4 hours 434 
after cyclophosphamide treatment (Fig. 2B). The referred hyperalgesia did not differ 435 
dependent on genotype suggesting that persistent activation of nociceptors by a 436 
developing noxious chemical stimuli is not driven by a requirement for NaV1.7 to be 437 
present. 438 
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Visceral afferent mechanosensitivity is blocked by TTX but is unaffected by 439 
deletion of NaV1.7 or blockade with a selective small-molecule NaV1.7 antagonist 440 
In order to distinguish between the multiple roles that NaV1.7 makes to nociceptive 441 
processing, we investigated the contribution of NaV1.7 to mechanosensitivity and 442 
chemosensitivity at the peripheral terminals of sensory neurons innervating the 443 
gastrointestinal tract. To do this multi-unit ex vivo extracellular electrophysiological 444 
recordings of lumbar splanchnic nerve activity were made from the distal colon of mice. 445 
Tissues were dissected free and cannulated to enable mechanical and chemical stimuli 446 
to be applied by luminal distension or bath superfusion. Phasic distension of the colon 447 
to noxious pressures (0-80 mm Hg) was used to model mechanical stimulation of the 448 
bowel and evoke increased afferent firing for the duration (60 second) of the distension. 449 
Consistent with previous reports, adaptation in the response to repeat stimulation (at 9 450 
minute intervals) was observed during subsequent distensions with the response 451 
stabilizing by the fourth to sixth distension (see Fig. 3A & C) (Hockley et al., 2014). In 452 
NaV1.7Nav1.8 mice, there was no significant difference in either the initial peak distension 453 
response or in the degree of tachyphylaxis observed during repeat distensions 454 
compared to littermate controls (Fig. 3C, P = 0.62, N = 13-14, 2-way repeated-measures 455 
(RM) ANOVA). Previous studies have suggested that not only the magnitude, but also 456 
the dynamic quality, of the distension paradigm used may be important for delineating 457 
gut motor events, specifically noxious stimuli (Sengupta & Gebhart, 1994; Booth et al., 458 
2008). Given the proposed role of NaV1.7 as a threshold channel contributing to the 459 
amplification of depolarizing stimuli in sensory neurons (Dib-Hajj et al., 2013), we used 460 
a slow ramp distension protocol to supramaximal distension pressures (0-145 mm Hg) 461 
in order to investigate the impact of loss of NaV1.7 on responses across a range of 462 
innocuous and noxious distending pressures. In littermate controls, afferent firing 463 
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increased proportionally to intraluminal pressure with a peak firing rate of 37.5 ± 5.7 464 
spikes/s at 145 mm Hg. Significantly less firing was observed in NaV1.7Nav1.8 mice to 465 
equivalent distending pressures (at 145 mm Hg, 25.7 ± 4.2 spikes/s; P < 0.0001, N = 19, 466 
2-way ANOVA). However, firing rates in NaV1.7Nav1.8 mice to ramp distension were 467 
unchanged within the physiologically-relevant 0-80 mm Hg range compared to controls 468 
(P > 0.05, Bonferroni’s post-hoc analysis). Within the supramaximal range (80 -145 mm 469 
Hg), there was a reduction in firing, suggesting NaV1.7 may be involved in transducing 470 
non-physiological extremes of pressure in the colon but not innocuous or even noxious 471 
mechanical stimuli.  472 
Given that NaV1.7 is ablated only in NaV1.8-positive neurons, it is possible that visceral 473 
afferents that are both sensitive to noxious mechanical stimuli and are negative for 474 
NaV1.8 may be contributory to the responses observed. In order to test this hypothesis, 475 
in a further set of experiments, repeat phasic distensions were continued and the effect 476 
of the selective small-molecule NaV1.7 antagonist PF-5198007 (100nM) was assessed 477 
on responses in both NaV1.7Nav1.8 and littermate control mice. Responses in littermate 478 
control mice to repeat phasic distensions were unchanged following pre-incubation 479 
with, and in the presence of, 100nM PF-5198007 compared to vehicle (Fig. 3E, P = 0.86, 480 
N = 7, 2-way RM ANOVA). Further, the afferent response following application of 100nM 481 
PF-5198007 in NaV1.7Nav1.8 mice also did not significantly differ from that observed in 482 
wild-type animals (P = 0.87, N = 6-7, 2-way RM ANOVA). However, irrespective of 483 
genotype, application of 100nM TTX to preparations did fully block afferent firing to 484 
noxious phasic distension (Fig. 3E). Together this shows that mechanosensitivity in 485 
visceral afferents is dependent on TTX-sensitive voltage-gated sodium channels but not 486 
NaV1.7. 487 
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Loss, or antagonism, of NaV1.7 does not alter visceral afferent responses to acute 488 
inflammatory and algogenic mediators 489 
To investigate the involvement of NaV1.7 in modulating visceral afferent sensitivity to 490 
inflammatory and algogenic mediators used in our in vivo studies, capsaicin and 491 
mustard oil were applied to distal colon preparations and visceral afferent responses 492 
recorded from both littermate and NaV1.7Nav1.8 mice, and in the presence or absence of 493 
100nM PF-5198007. In separate experiments, bradykinin and ATP, as inflammatory 494 
mediators typically present during injury or infection, and that may be evoked by 495 
mustard oil/cyclophosphamide treatment contributing to ongoing nociceptor 496 
sensitization were also tested.  497 
Responses to application of 500nM capsaicin did not differ between NaV1.7Nav1.8 mice 498 
and littermate mice in vehicle control experiments (0.1% DMSO; NaV1.7Nav1.8 vs. 499 
littermate; P = 0.50, N = 6 both groups, unpaired t-test, Fig. 4A). In addition, superfusion 500 
of 100nM PF-5198007 during, and 5 minutes prior to, capsaicin (500nM) application 501 
did not significantly change the evoked afferent discharge in either genotype 502 
(NaV1.7Nav1.8: 100nM PF-5198007 vs. 0.1% DMSO, P = 0.82, N = 6, unpaired t-test; 503 
littermate: 100nM PF-5198007 vs. 0.1% DMSO, P = 0.59, N = 6, unpaired t-test, Fig. 4A). 504 
Afferent firing evoked by mustard oil was also unchanged in both NaV1.7Nav1.8 mice and 505 
littermate controls (0.1% DMSO: NaV1.7Nav1.8 vs. littermate, P = 0.46, N = 6, unpaired t-506 
test, Fig. 4B), irrespective of the presence of NaV1.7 antagonist (NaV1.7Nav1.8: 100nM PF-507 
5198007 vs. 0.1% DMSO, P = 0.44, N = 6, unpaired t-test; littermate: 100nM PF-5198007 508 
vs. 0.1% DMSO, P = 0.93, N = 6, unpaired t-test, Fig. 4B). 509 
Bath superfusion of 1mM ATP in littermate mice resulted in significant afferent 510 
discharge with a peak change in firing of 1.39 ± 0.50 spikes/s. In NaV1.7Nav1.8 mice, the 511 
response was comparable to littermate controls (2.33 ± 0.80 spikes/s, P = 0.32, N = 7-8, 512 
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unpaired t-test). Responses to application of 1μM bradykinin were greater than that 513 
observed for ATP, however did not differ dependent on genotype (littermate, 9.11 ± 514 
3.32 vs. NaV1.7Nav1.8, 8.56 ± 3.04 spikes/s, P = 0.90, N = 7-8, unpaired t-test). Further, in 515 
distal colon preparations from littermate controls pre-incubated with 100nM PF-516 
5198007, peak firing response to 1μM bradykinin was unchanged (vehicle (0.1% 517 
DMSO) 5.16 ± 2.00 versus 100nM PF-5198007 4.31 ± 0.63 spikes/s, P = 0.70, N = 7, 518 
unpaired t-test); this was also true of tissues from NaV1.7Nav1.8 mice pre-incubated with 519 
the NaV1.7 antagonist (100nM PF-5198007; P = 0.17, N = 6-7, unpaired t-test). 520 
Collectively, these data suggest that NaV1.7 within the peripheral terminal of colonic 521 
sensory neurons is not required in order to transduce both noxious mechanical and 522 
chemical algogenic stimuli, in agreement with behavioral experiments. 523 
Localization of NaV expression in colonic sensory neurons 524 
We next investigated the expression of voltage-gated sodium channel α subunits 525 
present in colonic sensory neurons. Specifically, using single-cell qRT-PCR we examined 526 
the expression of mRNA transcripts for NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, 527 
NaV1.7, NaV1.8 and NaV1.9 in gut-projecting sensory neurons. Both lumbar splanchnic 528 
and pelvic innervation have been shown to contribute to the transmission of noxious 529 
stimuli from the distal colon (Brierley et al., 2004). As such, the expression of these 530 
channels was determined in colonic sensory neurons in dorsal root ganglia (DRG) T10 531 
to L1 levels (thoracolumbar: TL) that are known to possess the greatest number of 532 
sensory neurons projecting via the lumbar splanchnic nerve, and separately in DRG L5 533 
to S2 levels (lumbosacral: LS); the afferents from which have been shown to project 534 
predominantly via the pelvic nerve. Of the 30 cells collected per mouse (N = 3), the 535 
average size of colonic sensory neurons harvested was 32.0 ± 0.2 μm for TL (N = 3) and 536 
30.7 ± 1.0 μm for LS (N = 3). In the NaV1.7Nav1.8 mice used in the studies described here, 537 
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NaV1.7 was selectively ablated from all NaV1.8-positive sensory neurons. To confirm the 538 
proportion of colonic sensory neurons affected by this gene ablation, the expression of 539 
NaV1.7 and NaV1.8 was first examined. NaV1.7 was present in 100% of thoracolumbar 540 
and 95.6 ± 2.22% of lumbosacral colonic sensory neurons. High expression of NaV1.8 541 
was also observed in both thoracolumbar (95.6 ± 2.22 %) and lumbosacral (91.1 ± 4.44 542 
%) colonic sensory neuron populations. Importantly, significant co-expression of both 543 
these sodium channels in individual colonic sensory neurons was found, with 95.4% of 544 
NaV1.7-positive neurons also expressing NaV1.8, suggesting that the vast majority of 545 
colonic sensory neurons in NaV1.7Nav1.8 mice would be affected by the genetic deletion. 546 
The expression of the remaining tetrodotoxin-sensitive (TTX-S: NaV1.1, NaV1.2, NaV1.3, 547 
NaV1.4 and NaV1.6) and TTX-resistant voltage-gated sodium channels (TTX-R: NaV1.5 548 
and NaV1.9) was also determined (Catterall et al., 2005). Of the TTX-S sodium channels, 549 
NaV1.6 was present in the greatest frequency (86.7%; Fig. 5A) of thoracolumbar colonic 550 
sensory neurons after NaV1.7. Significant proportions of thoracolumbar colonic sensory 551 
neurons also expressed either NaV1.1 (44.4 ± 5.88 %), NaV1.2 (68.9 ± 8.89 %) or NaV1.3 552 
(53.3 ± 10.2 %), although co-expression was not always observed (see Fig. 5C). As 553 
expected, both the skeletal myocyte voltage-gated sodium channel NaV1.4 and the 554 
cardiac myocyte NaV1.5 channel were expressed by low proportions of thoracolumbar 555 
colonic sensory neurons (6.67 ± 6.67 % and 17.8 ± 5.88 %, respectively). In agreement 556 
with previous studies, mRNA transcripts for TTX-R NaV1.9 were observed in 84.4 ± 44.4 557 
% of thoracolumbar neurons (Hockley et al., 2016). By comparison, the expression of 558 
NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.7 and NaV1.8 did not significantly differ between 559 
populations of lumbosacral compared to thoracolumbar colonic sensory neurons (Fig. 560 
5A, all P > 0.05, TL vs. LS, unpaired t-test). Interestingly, significant differences were 561 
observed between the frequency of expression of NaV1.5 (TL vs. LS, P < 0.05, unpaired t-562 
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test) and NaV1.6 (TL vs. LS, P < 0.01, unpaired t-test) in lumbosacral compared to 563 
thoracolumbar colonic sensory neurons. Indeed, transcripts for both NaV1.5 and NaV1.6 564 
were observed in approximately half of lumbosacral colonic sensory neurons (48.9 ± 565 
8.01 % and 51.1 ± 5.88 %, respectively). The expression of NaV1.9 (which has been 566 
shown previously to contribute to afferent sensitivity of the lumbar splanchnic 567 
nerve(Hockley et al., 2014)) in lumbosacral colonic sensory neurons were consistent 568 
with the frequency of expression observed in the thoracolumbar populations (P = 0.42, 569 
N = 3, unpaired t-test). Taken together, these data not only support the expression of 570 
NaV1.7 by a majority of colonic sensory neurons innervating the distal colon, but also 571 
highlight an as yet unexplored complexity in the molecular patterning of voltage-gated 572 
sodium channels present in these neurons.  573 
Deletion of NaV1.7 impairs somatic noxious thermal thresholds, which can be 574 
recapitulated by NaV1.7 antagonism 575 
Given that no differences in acute visceral pain or referred hyperalgesia could be 576 
observed in mice lacking NaV1.7 in NaV1.8-positive neurons or to block of NaV1.7 by the 577 
selective inhibitor PF-5198007, we next sought to investigate the role of NaV1.7 in 578 
somatic acute pain behaviors. In order to investigate the contribution of NaV1.7 in 579 
NaV1.8-positive sensory neurons to the modulation of thermal thresholds, we utilized a 580 
ramping hotplate behavioral paradigm. In littermate controls, this latency was 261 ± 5 581 
seconds (N = 38) corresponding to a temperature rise of ~13.6°C (baseline floor 582 
temperature 31°C ramping to 44.6 ± 0.2°C; Fig. 6A). This increase in temperature 583 
required to evoke a behavioral response was equivalent to a previous study using a 584 
modified ramping Hargreaves’ test (Minett et al., 2014a). NaV1.7Nav1.8 mice showed an 585 
attenuated response to ramping hotplate with an augmented latency (274 ± 5 s) and 586 
significantly increased thermal threshold (46.1 ± 0.3°C, N = 36, P < 0.0001, unpaired t-587 
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test; Fig. 6A) in agreement with previous observations (Minett et al., 2014a). The 588 
attenuation of complex behaviors associated with the ramping hotplate test suggests 589 
involvement of NaV1.7 in pain signalling to noxious thermal stimulation of the skin 590 
under certain conditions.  591 
Using the ramping hotplate, we went on to confirm the ability for the selective NaV1.7 592 
inhibitor PF-5198007 to modulate thermal pain behaviors (see Fig. 6B). In littermate 593 
mice, application of PF-5198007 (1mg/kg P.O.) significantly increased the thermal 594 
threshold for observing pain behaviors with a concomitant increase in the latency to 595 
response when compared to vehicle controls (P < 0.01, N = 10, 2-way ANOVA with 596 
Bonferroni’s post-hoc vs. vehicle; Fig. 6B). In both vehicle and PF-5198007 treatment 597 
groups, the thermal threshold of NaV1.7Nav1.8 mice remained significantly greater than 598 
littermate controls but did not differ between groups. Application of a higher dose of 599 
PF-5198007 (3mg/kg P.O.) also led to an increase in thermal threshold during hotplate 600 
ramp, which was comparable to thresholds observed in NaV1.7Nav1.8 mice and 601 
significantly different from vehicle groups (P < 0.05, N = 10, 2-way ANOVA with 602 
Bonferroni’s post-hoc vs. vehicle). These data suggest that whilst pain behaviors can be 603 
evoked in the absence, or antagonism, of NaV1.7, the expression of NaV1.7 in sensory 604 
neurons modulates heat pain thresholds to noxious thermal stimuli. 605 
NaV1.7 also contributes to cutaneous afferent firing to both noxious hot, but not 606 
cold, thermal stimuli 607 
To investigate whether NaV1.7 was necessary for sensory transduction at the peripheral 608 
terminal of somatic afferents, ex vivo multi-unit electrophysiological recordings of the 609 
tibial nerve from skin-nerve preparations of NaV1.7Nav1.8 mice and littermate controls 610 
were made (Fig. 6C & D). In support of hotplate experiments, a ramping thermal stimuli 611 
(focal water jet from 36°C to 52°C (at ~0.4°C/sec)) was applied to the corium side of the 612 
28 
 
skin and the evoked nerve activity recorded. Total firing during the heat-evoked stimuli 613 
was significantly attenuated in NaV1.7Nav1.8 mice compared to littermate controls (Fig. 614 
6E, P < 0.0001, N = 26-29, 2-way ANOVA with Bonferroni’s post-hoc). Bath superfusion 615 
of 100nM TTX led to significant inhibition of firing regardless of genotype compared to 616 
vehicle controls (Fig. 6E, P < 0.05, N = 9-11 and P < 0.0001, N = 10-11, NaV1.7Nav1.8 and 617 
littermate controls, respectively, 2-way ANOVA with Bonferroni’s post-hoc), suggesting 618 
that the transduction of noxious thermal stimuli at the peripheral terminal of sensory 619 
afferents is enhanced by the presence of NaV1.7 in NaV1.8-positive neurons, but is 620 
dependent on other TTX-S NaVs that might be present. Application of 100nM PF-621 
5198007 in littermate controls was able to recapitulate the attenuated response 622 
observed in NaV1.7Nav1.8 mice (Fig. 6F, P < 0.05, N = 9-10, 2-way ANOVA with 623 
Bonferroni’s post-hoc vs. vehicle (0.1% DMSO)). In addition, PF-5198007 in NaV1.7Nav1.8 624 
mice further reduced afferent responses to heat ramp suggesting that afferent firing at 625 
the peripheral terminal is dependent predominantly on expression of NaV1.7 in NaV1.8-626 
positive sensory neurons. However, this does not discount contributions of NaV1.7 to 627 
other sensory populations spinally or supra-spinally involved in the nociceptive 628 
processing of thermal stimuli.  629 
In addition, we investigated cutaneous afferent firing to evoked cold stimuli by localized 630 
perfusion of a cooling perfusate over the receptive field from 36°C to ~6°C (at 631 
~0.4°C/sec). In previous studies, NaV1.7 has been shown to be involved in acetone-632 
induced cooling, but not noxious cold sensation (Minett et al., 2012). Responses evoked 633 
by cold stimulation of the skin did not differ between NaV1.7Nav1.8 mice and littermate 634 
controls (Fig. 6G, P > 0.05, N = 18, 2-way ANOVA with Bonferroni’s post-hoc), however 635 
application of 100nM TTX completely abolished cold-evoked responses compared to 636 
vehicle (P < 0.01, N = 6 and P < 0.0001, N = 5-6, littermate and NaV1.7Nav1.8 mice, 637 
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respectively, 2-way ANOVA with Bonferroni’s post-hoc). Finally incubation with the 638 
selective NaV1.7 antagonist PF-5198007 (100nM) did not significantly attenuate cold 639 
evoked afferent firing (Fig. 6H), supporting the posit that NaV1.7 does not contribute to 640 
the transduction or amplification of cold-evoked depolarizations at the peripheral 641 
terminal. 642 
Mesenteric nerve responses to phasic distension in human appendix are 643 
unaffected by inhibition of NaV1.7 644 
Finally, in order to understand whether our findings in murine visceral afferents 645 
translate to human we used ex vivo extracellular recordings of surgically resected 646 
appendices to investigate NaV1.7 function in response to mechanical stimuli. The human 647 
appendix has been used previously as a pre-clinical model of visceral nociception (Peiris 648 
et al., 2011). The appendix was cannulated and stimulated by repeat noxious ramp 649 
distension (0-60 mm Hg) and mesenteric nerve firing recorded. Ramp distension 650 
evoked a concomitant increase in human visceral afferent firing with a peak change in 651 
firing of 10.1 ± 1.5 spikes/s (N = 5), with reproducible responses observed to 652 
subsequent distensions. Application of PF-5198007 did not significantly impair visceral 653 
afferent firing to ramp distension at either low or high distending pressures (Fig. 7B, P = 654 
0.26, N = 5, 2-way RM ANOVA). This confirms our mouse data highlighting that NaV1.7 655 
appears not to significantly impact visceral afferent sensitivity to acute 656 
mechanosensation. As such, NaV1.7 imparts functionality on sensory neurons in a 657 
modality-specific manner and therefore the analgesic assessment of NaV1.7 antagonists 658 
should be determined in a mechanism-dependent fashion.      659 
 660 
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Discussion 661 
Nociceptive processing in somatic and visceral pain has common underlying pathways, 662 
including convergence in neuroanatomy, overlap in psychological representation and 663 
commonality in cellular transductions. However, important differences exist in the 664 
manifestation, perception and psychology of these pain modalities. Traditionally, 665 
visceral afferents are characterized based on mechanical sensitivity and activation by 666 
chemical mediators (including bradykinin and ATP (Su & Gebhart, 1998; Brierley et al., 667 
2004; Grundy, 2004)), with functional assessment required to define nociceptive 668 
properties. Compared to somatic counterparts, visceral sensory neurons almost 669 
exclusively possess characteristics attributed to nociceptors (unmyelinated C-fibres 670 
(Sengupta & Gebhart, 1994), peptidergic (Robinson et al., 2004) and high expression of 671 
NaV1.8/TTX-R sodium currents (Beyak et al., 2004)), yet collectively transduce 672 
innocuous unconscious and conscious sensations in addition to pain. As such, visceral 673 
sensory neurons do not fit well with classical views of nociceptors and established 674 
schema for nociceptive transduction pathways.   675 
Here, we add to this by showing that visceral pain signalling in vivo to acute and 676 
sensitizing noxious stimuli is independent of NaV1.7. We confirm by way of ex vivo 677 
electrophysiological recordings of mouse visceral afferent fibres that deletion of, or 678 
selective small-molecule antagonism of NaV1.7, does not attenuate responses to 679 
persistent noxious mechanical (including repeat phasic and sustained ramp distension) 680 
and chemical stimuli (including capsaicin, mustard oil, bradykinin and ATP). This lack of 681 
efficacy in NaV1.7 antagonism in blocking visceral afferent activation extends to 682 
recordings from resected human appendix tissues when applying noxious distending 683 
pressures. Surprisingly, mouse visceral sensory neurons almost always express NaV1.7 684 
suggesting that, whilst present, NaV1.7 appears not to contribute to the modulation of 685 
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afferent excitability to depolarizing stimuli, or the propagation of action potentials. 686 
Furthermore, the lack of phenotype observed in NaV1.7Nav1.8 mice suggests NaV1.7 is not 687 
necessary for transducing noxious visceral input centrally by NaV1.8-expressing 688 
neurons. By contrast somatically, deletion of NaV1.7 does modulate acute heat pain 689 
thresholds, which can be replicated using selective NaV1.7 antagonism. Strikingly, loss of 690 
NaV1.7 from NaV1.8-expressing neurons, or small-molecule antagonism, are able to 691 
attenuate afferent firing evoked by ramping heat stimuli applied to skin-nerve 692 
preparations. This implicates NaV1.7 in modulating thermal transduction sensitivity in 693 
somatic afferents. This was not true of cold stimuli, where NaV1.7 does not have a role in 694 
afferent responses. Our data demonstrates that whilst NaV1.7 does modulate defined 695 
somatic pain pathways, it is not required for those visceral pain modalities investigated 696 
here and advocates that selective pharmacological block of NaV1.7 in the viscera may 697 
prove ineffective in targeting chronic visceral pain caused by spontaneous nociceptor 698 
activity, sensitizing inflammatory mediators or evoked mechanical distension: principal 699 
clinical drivers of visceral pain. 700 
Voltage-gated sodium channels are vital for the transmission of painful stimuli in 701 
primary afferents. Importantly, the relative significance of individual sodium channels is 702 
dependent on the pain modality considered, with NaV1.7 essential in transducing 703 
somatic acute thermal and mechanical pain, in conjunction to inflammatory 704 
hyperalgesia and neuropathic allodynia (Minett et al., 2014b). Similarly, NaV1.8 is 705 
critical for extreme cold pain (Abrahamsen et al., 2008), with chemotherapy-induced 706 
allodynia dependent on NaV1.6 (Sittl et al., 2012; Deuis et al., 2013). Normal visceral 707 
nociceptor activity, by contrast, is dependent on both NaV1.8 (Laird et al., 2002) and 708 
NaV1.9 (Hockley et al., 2014). Surprisingly, the role of NaV1.7 in visceral pain processing 709 
is poorly understood in spite of human genetic data linking NaV1.7 to pain signalling.  710 
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Substantive evidence for the involvement of NaV1.7 in visceral pain processing comes 711 
from human genetic studies. Patients with congenital insensitivity to pain linked to 712 
mutations in NaV1.7 do not feel pain, including pain originating from internal structures 713 
(broken bones (Cox et al., 2006; Goldberg et al., 2007)) and hollow organs (e.g. during 714 
appendicitis or child-birth (Melzack & Wall, 1988; Zimmermann et al., 1988)). 715 
Mutations in SCN9A gene encoding NaV1.7 are also causal in paroxysmal extreme pain 716 
disorder (PEPD) where severe burning pain may occur in rectal, ocular and mandibular 717 
regions. Intriguingly, defecation and micturition can both trigger such rectal pain 718 
attacks (Fertleman et al., 2006; Meglic et al., 2014), implicating hypersensitivity of 719 
visceral mechanoreceptors in initiating pain attacks. Whilst NaV1.7 is linked with 720 
multiple aspects of the pain pathway, this is the first report detailing the contribution of 721 
NaV1.7 to visceral pain processing. Using single-cell qRT-PCR of gut-specific sensory 722 
neurons we show that mRNA transcripts for NaV1.7 are expressed by the vast majority 723 
of colonic sensory neurons, consistent with NaV1.7 immunoreactivity in extrinsic 724 
afferent terminals of the distal colorectum (Feng et al., 2015). Co-expression of NaV1.7 725 
in NaV1.8-positive neurons was substantial in gut-projecting populations, suggesting 726 
that nearly all visceral sensory neurons would be affected by NaV1.8-specific knockout 727 
of NaV1.7 (Nassar et al., 2004). However, it is possible that some NaV1.7-positive NaV1.8-728 
negative colonic neurones remain, which may be sufficient to maintain pain behaviours. 729 
Visceral afferent firing to mechanical and chemical activation were unaffected following 730 
loss of, or antagonism of, NaV1.7, but could be blocked by TTX as shown previously 731 
(Campaniello et al., 2016). As such, TTX-S NaVs other than NaV1.7 are involved in 732 
transducing noxious visceral stimuli. Established roles for TTX-R NaV1.8 and NaV1.9 733 
correlate well with their extensive expression shown here; however little is known 734 
about the expression of TTX-S NaVs within a viscerally-projecting population. NaV1.6 is 735 
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essential in pelvic afferent endings for spike initiation and repetitive firing (Feng et al., 736 
2015), a concept that would fit with the extensive presence of NaV1.6 mRNA transcripts 737 
observed here. Further, using toxin antagonists of NaV1.7 (ProTx-II) and NaV1.6 (μ-738 
conotoxin GIIIa and μ-conotoxin PIIIa), a requirement on NaV1.6, but not NaV1.7, was 739 
observed for the encoding of stretch-sensitive pelvic afferents (Feng et al., 2015). Taken 740 
together, these observations present compelling evidence that NaV1.7 is redundant in 741 
visceral afferent nociception to spontaneous or evoked noxious stimuli.  742 
Clearly whilst not necessary for normal sensation in the gut, the high relative expression 743 
of NaV1.7 suggests that aberrant NaV1.7 function, such as that present in some 744 
monogenic pain disorders, could significantly impact visceral sensation. Intriguingly, 745 
the propensity for mutations in NaV1.7 to evoke regional pain phenotypes in PEPD 746 
patients (i.e. rectal and not ‘true visceral’ pain) could be driven by differences we 747 
observe here in the expression of some sodium channels (NaV1.5(Renganathan et al., 748 
2002) and NaV1.6(Cummins et al., 2005)) located in thoracolumbar, versus lumbosacral, 749 
visceral sensory neurons. Precedent for background neuronal phenotype contributing 750 
to the manifestation of functional effects already exists with the same mutation in 751 
NaV1.7 causing hypo- and hyper-excitability when expressed in either sympathetic or 752 
sensory neurons (Rush et al., 2006). The extensive expression of NaV1.7 suggests that 753 
mutations subverting its endogenous function may significantly alter phenotype even if 754 
not required for that pain modality normally. As such it is possible that non-canonical 755 
roles of NaV1.7 may help explain the contradiction of how CIP patients associated with 756 
loss of NaV1.7 do not feel visceral pain. For example, recent evidence of NaV1.7 deletion 757 
upregulating endogenous opioid expression suggests a complex transcriptional 758 
modulatory, as well as electrogenic, contribution by NaV1.7, however this did not alter 759 
the expression of other NaV subtypes present in DRG (Minett et al., 2015). Importantly, 760 
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the use of a selective small-molecule antagonist of NaV1.7 enables us to discount 761 
developmental differences in gene deletion studies in the phenotypes observed here. 762 
Comparison with somatic pain behaviors enables confirmation of a modality-specific 763 
action for NaV1.7 expression and confirms the ability of the antagonist PF-5198007 in 764 
replicating gene deletion studies. NaV1.7 is required for modulating heat pain 765 
thresholds after burn injury (Shields et al., 2012) and for acute noxious heat sensing in a 766 
population of NaV1.8-negative neurons (Minett et al., 2012). Surprisingly, we found 767 
using an adapted ramping hotplate test that loss of NaV1.7 from NaV1.8-positive neurons 768 
could also alter acute heat pain thresholds and this could be recapitulated using PF-769 
5198007. In all cases, mice remained sensitive to noxious heat, suggesting that NaV1.7 is 770 
not required in NaV1.8-expressing neurons but can modulate the thermal threshold 771 
sensitivity. Notably, we observed a desensitization of the heat pain threshold from 772 
~44°C by 2-3°C following antagonism of NaV1.7, as such fixed temperature hotplate 773 
tests typically used to measure withdrawal latencies at 50°C or 55°C would be above 774 
threshold in either case masking potential phenotypic differences. A similar non-775 
redundant role for NaV1.7 in NaV1.8-expressing neurons was observed to an adapted 776 
Hargreaves’ test (Minett et al., 2014a). This further highlights the involvement of 777 
multiple sub-populations of neurons on stimulus-intensity specific responses 778 
underpinning noxious thermal detection. 779 
In summary, using a combination of gene deletion knockout mice and pharmacological 780 
tool molecule we demonstrate that NaV1.7, although expressed extensively by gut-781 
projecting sensory neurons, contributes minimally to visceral pain pathways associated 782 
with algogenic sensitizing chemicals and evoked activation of visceral afferents by 783 
noxious stimuli. The patterning of sodium channel expression shown here reveals a 784 
previously unstudied molecular complexity to visceral sensory neurons. Combined with 785 
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a detailed study of somatic thermal sensitivity, we show that assessment of candidate 786 
analgesic targets to pain mechanisms must be considered in a modality-specific manner. 787 
As such, NaV1.7 antagonism of peripheral visceral afferents may not represent a viable 788 
therapeutic rationale for the treatment of chronic visceral pain associated with evoked 789 
distension or inflammation of the viscera.  790 
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Figure Legends 791 
Table 1  792 
Patients details from which resected appendix specimens were used. Appendix 793 
specimens from 5 patients were collected and used in electrophysiological nerve 794 
recordings.   795 
Figure 1 796 
Spontaneous visceral-pain related behaviors in NaV1.7Nav1.8 and littermate mice 797 
following intracolonic administration of capsaicin (A and C) or mustard oil (B and D). 798 
Number of acute pain related behaviors (licking of abdomen, stretching, abdominal 799 
retractions) induced by capsaicin (A) or mustard oil (B) during a 20 min period. 800 
Referred mechanical hyperalgesia (evaluated by stimulation of the abdomen with von 801 
Frey filaments) was measured 20 min after the administration of capsaicin (C) or 802 
mustard oil (D). Mean ± SEM of values obtained in 6-10 animals. *P < 0.05 and **P < 803 
0.01 vs. vehicle. 804 
Figure 2 805 
Visceral pain related behaviors evoked by cyclophosphamide-induced cystitis in 806 
NaV1.7Nav1.8 and littermate mice. (A) Behavioral pain responses were recorded at 30 807 
minute intervals during the 240 min observation period after cyclophosphamide 808 
injection. (B) Referred mechanical hyperalgesia was evaluated by stimulation of the 809 
abdomen with von Frey filament 4h after cyclophosphamide administration. Mean 810 
± SEM of values obtained in 6-10 animals. *P < 0.05 and **P < 0.01, vs. vehicle. 811 
 812 
Figure 3 813 
Visceral afferent responses to noxious distension of the distal colon in NaV1.7Nav1.8 mice 814 
and following small-molecule NaV1.7 antagonism. Example rate histogram of colonic 815 
37 
 
splanchnic nerve activity and intraluminal pressure trace to repeat phasic distension (0-816 
80 mm Hg; 60 s; 9 min intervals) in NaV1.7Nav1.8 (B) and littermate (A) mice. (C) Peak 817 
change in firing rate during phasic distensions in both genotypes (P = 0.46, 2-way 818 
repeated-measures ANOVA). (D) Average firing rates to ramp distension (0-145 mm 819 
Hg) at 5 mm Hg increments in littermate and NaV1.7Nav1.8 mice. (E) Effect of 100nM PF-820 
5198007, vehicle (0.1% DMSO) or 100nM TTX on total firing evoked during repeat 0-80 821 
mm Hg phasic distensions in littermate and NaV1.7Nav1.8 mice.  822 
Figure 4 823 
Effect of capsaicin and mustard oil on visceral afferent responses. Change in peak firing 824 
rate to application of 500nM capsaicin (A) and 250μM mustard oil (B) in littermate and 825 
NaV1.7Nav1.8 mice, both in the absence and presence of 100nM PF-5198007.  826 
Figure 5 827 
Expression of voltage-gated sodium channel mRNA transcripts in mouse colonic 828 
sensory neurons by single-cell qRT-PCR. (A) Proportions of thoracolumbar and 829 
lumbosacral colonic sensory neurons expressing transcripts for NaV1.1, NaV1.2, NaV1.3, 830 
NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8 and NaV1.9. (B) Relative expression of NaV 831 
transcripts in thoracolumbar and lumbosacral colonic sensory neurones (C) Co-832 
expression analysis of voltage-gated sodium channels in both thoracolumbar and 833 
lumbosacral colonic sensory neuronal populations. Each segment in the wheel-diagrams 834 
is representative of a single cell with a coloured segment signifying positive expression.  835 
Figure 6 836 
Somatic pain behaviors and tibial nerve activity to noxious thermal stimulation in 837 
NaV1.7Nav1.8 and littermate mice. (A) Thermal pain thresholds in NaV1.7Nav1.8 mice are 838 
significantly increased following ramping hotplate behavioral testing. (B) Average 839 
thermal pain thresholds following the application of selective NaV1.7 antagonist PF-840 
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5198007 (1 or 3mg/kg) or vehicle in NaV1.7Nav1.8 and littermate mice. Example raw 841 
traces, rate histogram and temperature recordings of tibial nerve activity in littermate 842 
(C) and NaV1.7Nav1.8 mice (D). (E) Sum firing of tibial nerve activity during focal heat 843 
stimulation in skin-nerve preparations of NaV1.7Nav1.8 and littermate mice in the 844 
presence of TTX (100nM) or vehicle (0.1% distilled H2O). ####P < 0.0001, NaV1.7Nav1.8 845 
baseline vs. littermate baseline. (F) Effect of PF-5198007 on evoked tibial nerve firing 846 
by heat stimulation in NaV1.7Nav1.8 and littermate mice. (G) Sum firing of tibial nerve 847 
activity during focal cold stimulation in skin-nerve preparations of NaV1.7Nav1.8 and 848 
littermate mice in the presence of TTX (100nM) or vehicle (0.1% distilled H2O). (H) 849 
Effect of PF-5198007 on evoked tibial nerve firing by cold stimulation in NaV1.7Nav1.8 850 
and littermate mice. *P < 0.05, **P < 0.01, ****P < 0.0001. 851 
Figure 7 852 
Effect of selective small-molecule antagonism of NaV1.7 in resected human appendices 853 
following repeat noxious distension. (A) Example rate histogram of appendix 854 
mesenteric nerve activity and intraluminal pressure trace following repeat ramp 855 
distension (0-60 mm Hg; 10 min interval). Application of PF-5198007 was initiated at 856 
the start of the black bar and maintained for 50 min during which distensions were 857 
continued. (B) Average firing rates to repeat ramp distension (0-60 mm Hg; N = 5) of 858 
human appendix prior to, and after, addition of PF-5198007; neither low-threshold or 859 
high-threshold afferent firing is affected by antagonism of NaV1.7. Both change in peak 860 
firing rate (C) and total afferent firing (D; Area Under Curve) were unchanged by bath 861 
superfusion with PF-5198007 (N = 5). 862 
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Table 1 1084 
# Disease Operation Tissue Age Sex 
1 Cancer Right hemicolectomy Appendix 83 F 
2 Cancer Right hemicolectomy Appendix 42 F 
3 Cancer Right hemicolectomy Appendix 72 F 
4 Slow Transit Constipation Subtotal Colectomy Appendix 69 M 
5 Cancer Right hemicolectomy Appendix 70 M 
   Mean age / M:F ratio 67 1:1.5 
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